

# Minomic International Ltd




- A company whose focus is on commercialising biomarkers for diagnosis and treatment of major diseases
- Incorporated in 2007 to commercialise diagnostic assays – the first one for Prostate Cancer (CaP)
- CaP Diagnostic scheduled to be market ready in 2012
- When product complete, Minomic will enter US\$3 billion market
- Dr Brad Walsh   [brad.walsh@minomic.com](mailto:brad.walsh@minomic.com)   0413 231 296

# Company Overview

- Company Genesis
  - Formed 2007 after 5 years prior research
  - Experienced biotech and business team
- Key Highlights
  - Prostate cancer is #1 male cancer
  - \$3 B market in PSA testing
  - PSA test is not good enough
  - Minomic has exclusive license to a prostate cancer detecting antibody
  - Minomic owns the antigen to this antibody
- Management Credentials
  - Chairman – Experienced businessman and Pharmacist for 35 years
  - Board members – Experienced finance exec with public company expertise, Experienced venture capital provider and investor
  - Chief Scientific Officer – 30 years in biotech industry in diagnostics and proteomics
  - Scientific Advisory Panel of eminent Australian scientists

# Pipeline



# Lead Product – Vital Information

- Product Name - MiStat
- Class III *In Vitro* Diagnostic
- Stage of Development
  - Designing study of 400 tests for TGA, CE mark and FDA approval
- Evaluation Results – Proof of Concept testing
  - Test sensitivity 70% Specificity 75%
  - n = 54 patients
    - n = 14 Benign Prostatic Hyperplasia
    - n = 6 healthy controls

# Lead Product – Commercialisation Strategy

- Size of Market
  - 67.6 Million PSA Tests in 2009
  - Value of Market > \$3.0 billion in 2009
- Competitive Advantage
  - Minomic Test statistics sensitivity 70% and specificity 75%
  - **Compare to** PSA Test statistics 40% sensitivity and 81% specificity
- Partnership Status - NDA with 2 FACS companies and draft collaboration agreement with one of these
- First Sales Expected in 2012

## Financials as of 30 March 2011

- Cash Raised to Date
  - \$5.2 M
  - No debt
- Ownership Structure
  - Public unlisted
  - 150 shareholders